SEC Form 4 · accession 0001209191-19-012296
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederic Pla
Officer — COO
Period of report
Feb 19, 2019
Accepted (ET)
Feb 21, 2019 · 7:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 19, 2019 | M | 1,500 | $31.98 | A | 41,178 | D | |
| Common StockF1 | Feb 19, 2019 | M | 1,400 | $27.00 | A | 42,578 | D | |
| Common StockF1 | Feb 19, 2019 | M | 2,800 | $27.48 | A | 45,378 | D | |
| Common StockF2,F3,F4,F1 | Feb 19, 2019 | S | 6,084 | $82.9283 | D | 39,294 | D | |
| Common StockF2,F3,F5,F1 | Feb 19, 2019 | S | 3,616 | $83.5524 | D | 35,678 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $31.98 | Feb 19, 2019 | M | 1,500 | D | — | Jan 1, 2025 | Common Stock | 1,500 | 78,667 | D |
| Employee Stock Option (right to buy) HoldingF7 | $27.00 | Feb 19, 2019 | M | 1,400 | D | — | Feb 16, 2026 | Common Stock | 1,400 | 19,167 | D |
| Employee Stock Option (right to buy) HoldingF8 | $27.48 | Feb 19, 2019 | M | 2,800 | D | — | Jan 31, 2027 | Common Stock | 2,800 | 46,453 | D |
Explanation of responses
- F1Includes an aggregate of 22,874 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on December 10, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $82.30 to $83.29.
- F5Represents weighted average sale price. Actual sale prices ranged from $83.30 to $83.96.
- F6The option became exercisable as to 25% of the shares on January 1, 2016, and became exercisable as to 1/48th of the shares each full month thereafter.
- F7The option became exercisable as to 25% of the shares on February 16, 2017, and became exercisable as to 1/48th of the shares each full month thereafter.
- F8The option became exercisable as to 25% of the shares on January 31, 2018, and becomes exercisable as to 1/48th of the shares each full month thereafter.